| | | | | | | | | | |
|
|
| Dockets Entered
On December 14, 2006
Table of Contents
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
| 1978N-0065
|
| Skin Bleaching Drug Products
|
|
|
| 1990S-0308
|
| Generic Drug Speeches & Policy and Procedure Guides
|
|
|
| 2005H-0271
|
| Civil Money Penalty: TMJ Implants, Inc.
|
|
|
| 2006D-0336
|
| Guidance for Industry and Food and Drug Administration Staff; Commercially Distributed Analyte Specific Reagents (ASRs): Frequently Asked Questions
|
|
|
| 2006D-0383
|
| Characterization and Qualification of Cell Substrates and Other Biological Starting Materials Used in the Production of Viral Vaccines for the Prevention and Treatment of Infectious Diseases
|
|
|
| 2006N-0061
|
| Charging for Investigational Drugs
|
|
|
| 2006N-0062
|
| Expanded Access to Investigational Drugs for Treatment Use
|
|
|
| 2006N-0416
|
| Use of Ozone-Depleting Substances; Removal of Essential Use Designations
|
|
|
| 2006N-0464
|
| Electronic Submission of Regulatory Information, and Creating an Electronic Platform for Enhanced Information Management; Public Hearing
|
|
|
| 2006P-0371
|
| Immediately add a black box warning regarding the risks of tendinopathy and tendon rupture to the product labels of all fluoroquinolone antibiotics presently on the market in the United States
|
|
|
| 2006P-0394
|
| Revise the labeling requirements for eggs sold in the United States
|
|
|
| 2006P-0415
|
| Petition Seeking Regulation of Cloned Animals
|
|
|
| 2006P-0442
|
| Determine that Wyeth Pharmaceuticals, Inc. discontinued its previously-approved formulation of the Reference Listed Drug Zosyn (piperacillin and tazobactam for injection), 40.5 gram pharmacy bulk via
|
|
|
|
|
|
| 2006P-0444
|
| Stay the potential grant effective approval of ANDA for 77-536 for moexipril hydrochloride tablets
|
|
|
| 2006P-0510
|
| ANDA Suitability for Propoxyphene Hydrochloride 65 mg and Acetaminophen 325 mg Tablets
|
|
|
| 2006P-0511
|
| Stay any action to grant approval for Oxycodone Hydrochloride extended release tablets, ANDA 77-822
|
|
|
| 2006P-0513
|
| Determine that the Reference Listed Drug, Hydrochlorothiazide Tablets USP 100 mg, was voluntarily discontinued from sale in the US for reasons other than safety or effectiveness
|
|
|
| 1978N-0065
|
| Skin Bleaching Drug Products
|
|
|
| EC
139
|
| DERMAdoctor
|
| Vol #:
|
| 14
|
|
|
| 1990S-0308
|
| Generic Drug Speeches & Policy and Procedure Guides
|
|
|
| RPT
772
|
| Statistical Report - Month of November 2006
|
| Vol #:
|
| 55
|
|
|
| 2005H-0271
|
| Civil Money Penalty: TMJ Implants, Inc.
|
|
|
| EXB 170
|
| R-165 L.J. Broutman & Assoc. Material Characterization File 53-924)
|
| Vol #:
|
| 176
|
|
|
| EXB 171
|
| R-166 Structural Performance Evaluation of TMJ Temporomandibular Joint Prostheses
|
| Vol #:
|
| 177
|
|
|
| EXB 172
|
| R-167 Fenite Element Analysis of the Christensen/Chase Condylar Prostheses
|
| Vol #:
|
| 178
|
|
|
| EXB 173
|
| R-168 Structural Performance Evaluation of the TMJ Metal Condylar Prosthesis, by Design Sciences
|
| Vol #:
|
| 179
|
|
|
| EXB 174
|
| R-169 Final Report: Fenite Element Analysis of the TMJ Condylar Component
|
| Vol #:
|
| 180
|
|
|
| EXB 175
|
| R-170 An In Vivo Determination of Kinematics and Kinetics of the TMJ (Final Report )
|
| Vol #:
|
| 181
|
|
|
| EXB 176
|
| R-171 Final Report: Fatigue Testing of TMJ Implant System
|
| Vol #:
|
| 182
|
|
|
| EXB 177
|
| R-172 Final Report: Fatigue Testing of TMJ Implant System
|
| Vol #:
|
| 183
|
|
|
| EXB 178
|
| R-173 Factographic Analysis of TMJ ImplantsProstheses by Hauser Laboratories
|
| Vol #:
|
| 184
|
|
|
| EXB 179
|
| R-174 Report for TMJ Implant Inc. Particle from Pin on Disk Tests
|
| Vol #:
|
| 185
|
|
|
| EXB 180
|
| R-175 Final Report: Wear Testing of TMJ Implant System
|
| Vol #:
|
| 186
|
|
|
| EXB 181
|
| R-176 The Wear of Metal-Metal and Acrylic-Metal Total Temporomandibular Joints
|
| Vol #:
|
| 187
|
|
| | | | | | | | |
|
|
| EXB 182
|
| R-177 Wear Facet Analysis Rev A
|
| Vol #:
|
| 188
|
|
|
| EXB 183
|
| R-178 Temporomandibular Joint Arthroplasty Using Metal on Metal
|
| Vol #:
|
| 189
|
|
|
| EXB 184
|
| R-179 A Report for Reciprocating Wear Testing of a PMMA Temporomandibular Joint (404-302.05
|
| Vol #:
|
| 190
|
|
|
| EXB 185
|
| R-180 Wear Testing TMJ Implants' Fossa-Eminence and Condylar Prosthesis
|
| Vol #:
|
| 191
|
|
|
| EXB 186
|
| R-181 Scanning Electron Microscope Study of Excised Cobalt-Chromium Temporomandibular Impla
|
| Vol #:
|
| 192
|
|
|
| EXB 187
|
| R-182 PMMA/Metal Testing Bench Test Stress Analysis
|
| Vol #:
|
| 193
|
|
|
| EXB 188
|
| R-183 A Three-Dimensional Mathematical Model of Temporamandibular Joint Loading
|
| Vol #:
|
| 194
|
|
|
| EXB 189
|
| R-184 Static Load Testing of TMJ Implant Pairs with Cobalt -Chromium and PMMA Articular He
|
| Vol #:
|
| 195
|
|
|
| EXB 190
|
| R-185 The Effect of Location of the Pull-out Load of Condylar Bone Screws
|
| Vol #:
|
| 196
|
|
|
| EXB 191
|
| R-186 Mating Tolerances of Condyle/Fossa Components of the Christensen-Chase TMJ Implant
|
| Vol #:
|
| 197
|
|
|
| EXB 192
|
| R-186 Mating Tolerances of Condyle/Fossa Components of the Christensen-Chase TMJ Implant
|
| Vol #:
|
| 198
|
|
|
| 2006D-0336
|
| Guidance for Industry and Food and Drug Administration Staff; Commercially Distributed Analyte Specific Reagents (ASRs): Frequently Asked Questions
|
|
|
| C
3
|
| Critical Connection
|
| Vol #:
|
| 1
|
|
|
| 2006D-0383
|
| Characterization and Qualification of Cell Substrates and Other Biological Starting Materials Used in the Production of Viral Vaccines for the Prevention and Treatment of Infectious Diseases
|
|
|
|
|
|
|
| C 208
|
| E. Best, RN
|
| Vol #:
|
| 12
|
|
|
| C 209
|
| R and L Larson
|
| Vol #:
|
| 12
|
|
|
| C 210
|
| J and H Costello
|
| Vol #:
|
| 12
|
|
|
| C 211
|
| M. Vilim
|
| Vol #:
|
| 12
|
|
|
| C 212
|
| M. Velosa
|
| Vol #:
|
| 12
|
|
|
| C 213
|
| M. Gillespie
|
| Vol #:
|
| 12
|
|
|
| C 214
|
| Dr. Richard J. Ohm
|
| Vol #:
|
| 12
|
|
|
| C 215
|
| T. Ehlinger
|
| Vol #:
|
| 12
|
|
|
| C 216
|
| H and M Pahren
|
| Vol #:
|
| 12
|
|
|
| C 217
|
| R. Thoman
|
| Vol #:
|
| 12
|
|
|
| C 218
|
| M. Mann
|
| Vol #:
|
| 12
|
|
|
| C 219
|
| C. Suriano
|
| Vol #:
|
| 12
|
|
|
| C 220
|
| L. Israel
|
| Vol #:
|
| 12
|
|
|
| C 221
|
| A. Bell
|
| Vol #:
|
| 12
|
|
|
| C 222
|
| C. Buckley
|
| Vol #:
|
| 12
|
|
|
| C 223
|
| D. Damiano
|
| Vol #:
|
| 12
|
|
|
| C 224
|
| N. Cougher
|
| Vol #:
|
| 12
|
|
|
| C 225
|
| L. Diehl
|
| Vol #:
|
| 12
|
|
|
| C 226
|
| E. Adams
|
| Vol #:
|
| 12
|
|
|
| C 227
|
| P. Juergens
|
| Vol #:
|
| 12
|
|
|
| C 228
|
| P. Schlitz
|
| Vol #:
|
| 12
|
|
| | | | | | | | |
|
|
| REF
1
Attachment
|
| HF-26
|
| Vol #:
|
| 1
|
|
|
| 2006N-0464
|
| Electronic Submission of Regulatory Information, and Creating an Electronic Platform for Enhanced Information Management; Public Hearing
|
|
|
| APE 3
|
| Alston & Bird, LLP
|
| Vol #:
|
| 1
|
|
|
| C 1
|
| Comprehensive Clinical Trials, LLC
|
| Vol #:
|
| 1
|
|
|
| EC 22
|
| Dr. S. Albert Edwards
|
| Vol #:
|
| 2
|
|
|
| EC 23
|
| Northrop Grumman Corporation
|
| Vol #:
|
| 2
|
|
|
| EMC 1
|
| NGS, Newtech Global Soluctions LLC
|
| Vol #:
|
| 1
|
|
|
| LST 1
|
| Panelists for the Part 15 Public Hearing
|
| Vol #:
|
| 1
|
|
|
| LST 2
|
| Part 15 Public Hearing Schedule
|
| Vol #:
|
| 1
|
|
|
| 2006P-0371
|
| Immediately add a black box warning regarding the risks of tendinopathy and tendon rupture to the product labels of all fluoroquinolone antibiotics presently on the market in the United States
|
|
|
|
|
|
| EC
12
|
| Mrs. Margaret Lynch
|
| Vol #:
|
| 1
|
|
|
| 2006P-0394
|
| Revise the labeling requirements for eggs sold in the United States
|
|
|
| EC
445
|
| Mr. leslie swift
|
| Vol #:
|
| 7
|
|
|
| 2006P-0415
|
| Petition Seeking Regulation of Cloned Animals
|
|
|
| SUP
1
Attachments
|
| Center for Food Safety
|
| Vol #:
|
| 2
|
|
|
| 2006P-0442
|
| Determine that Wyeth Pharmaceuticals, Inc. discontinued its previously-approved formulation of the Reference Listed Drug Zosyn (piperacillin and tazobactam for injection), 40.5 gram pharmacy bulk via
|
|
|
|
|
|
| C 2
|
| Wyeth Pharmaceuticals
|
| Vol #:
|
| 1
|
|
|
| 2006P-0444
|
| Stay the potential grant effective approval of ANDA for 77-536 for moexipril hydrochloride tablets
|
|
|
| LET 1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
| 2006P-0510
|
| ANDA Suitability for Propoxyphene Hydrochloride 65 mg and Acetaminophen 325 mg Tablets
|
|
|
| ACK 1
|
| FDA / DDM to Lachman Consultant Services, Inc.
|
| Vol #:
|
| 1
|
|
|
| CP 1
|
| Lachman Consultant Services, Inc.
|
| Vol #:
|
| 1
|
|
|
| 2006P-0511
|
| Stay any action to grant approval for Oxycodone Hydrochloride extended release tablets, ANDA 77-822
|
|
|
| ACK 1
|
| FDA/DDM to Kleinfeld, Kaplan and Becker, LLP
|
| Vol #:
|
| 1
|
|
|
| PSA 1
|
| Kleinfeld, Kaplan and Becker, LLP
|
| Vol #:
|
| 1
|
|
|
| 2006P-0513
|
| Determine that the Reference Listed Drug, Hydrochlorothiazide Tablets USP 100 mg, was voluntarily discontinued from sale in the US for reasons other than safety or effectiveness
|
|
|
| ACK 1
|
| FDA/DDM to Caraco Pharmaceutical Laboratories, Ltd.
|
| Vol #:
|
| 1
|
|
|
| CP 1
|
| Caraco Pharmaceutical Laboratories, Ltd.
|
| Vol #:
|
| 1
|
|